Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Hepatitis

  Free Subscription


Articles published in Arch Virol

Retrieve available abstracts of 37 articles:
HTML format



Single Articles


    May 2022
  1. BOGLIONE L, De Benedetto I, Dodaro V, Chiecchio M, et al
    Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B.
    Arch Virol. 2022 May 22. pii: 10.1007/s00705-022-05466.
    PubMed     Abstract available


    March 2022
  2. QU C, Li Y, Li Y, Pan Y, et al
    Full-length MAVS, a mitochondrial antiviral-signaling protein, inhibits hepatitis E virus replication, requiring JAK-STAT signaling.
    Arch Virol. 2022 Mar 24. pii: 10.1007/s00705-022-05415.
    PubMed     Abstract available


    February 2022
  3. SALARI N, Darvishi N, Hemmati M, Shohaimi S, et al
    Global prevalence of hepatitis C in prisoners: a comprehensive systematic review and meta-analysis.
    Arch Virol. 2022 Feb 14. pii: 10.1007/s00705-022-05382.
    PubMed     Abstract available


    January 2022
  4. MESHRAM RJ, Kathwate GH, Gacche RN
    Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections.
    Arch Virol. 2022 Jan 28. pii: 10.1007/s00705-022-05375.
    PubMed     Abstract available


  5. WOLF JM, Mazeto TK, Pereira VRZB, Simon D, et al
    Recent molecular evolution of hepatitis B virus genotype F in Latin America.
    Arch Virol. 2022 Jan 25. pii: 10.1007/s00705-022-05376.
    PubMed     Abstract available


  6. XU R, Wang H, Huang J, Wang M, et al
    Complete genome sequencing and evolutionary analysis of hepatitis C virus subtype 6a, including strains from Guangdong Province, China.
    Arch Virol. 2022 Jan 20. pii: 10.1007/s00705-021-05358.
    PubMed     Abstract available


    November 2021
  7. SILVA LA, Camargo BR, Araujo AC, Batista TL, et al
    Easily purified baculovirus/insect-system-expressed recombinant hepatitis B virus surface antigen fused to the N- or C-terminus of polyhedrin.
    Arch Virol. 2021 Nov 28. pii: 10.1007/s00705-021-05305.
    PubMed     Abstract available


  8. OKSUZ Z, Ucbilek E, Serin MS, Yaras S, et al
    Possible relationship between IL28B rs12979860 and TLR2 -196 to -174 del/ins polymorphisms and the liver fibrosis stage in hepatitis C patients.
    Arch Virol. 2021 Nov 24. pii: 10.1007/s00705-021-05302.
    PubMed     Abstract available


  9. LIU J, Wang Z, Tang J, Tang R, et al
    Correction to: Hepatitis C virus core protein activates Wnt/beta-catenin signaling through multiple regulation of upstream molecules in the SMMC-7721 cell line.
    Arch Virol. 2021 Nov 4. pii: 10.1007/s00705-021-05275.
    PubMed    


  10. CHEN Y, Cai S, Zhang Y, Lai Z, et al
    First identification and genomic characterization of equine hepacivirus subtype 2 in China.
    Arch Virol. 2021;166:3221-3224.
    PubMed     Abstract available


    September 2021
  11. SHEN H, Liu S, Ding M, Gu H, et al
    A quadruple recombination event discovered in hepatitis E virus.
    Arch Virol. 2021 Sep 24. pii: 10.1007/s00705-021-05251.
    PubMed     Abstract available


  12. CHEN Z, Shi SH, Huang Y, Huang CQ, et al
    Differential metabolism-associated gene expression of duck pancreatic cells in response to two strains of duck hepatitis A virus type 1.
    Arch Virol. 2021 Sep 5. pii: 10.1007/s00705-021-05199.
    PubMed     Abstract available


  13. OLAGBENRO M, Anderson M, Gaseitsiwe S, Powell EA, et al
    In silico analysis of mutations associated with occult hepatitis B virus (HBV) infection in South Africa.
    Arch Virol. 2021 Sep 1. pii: 10.1007/s00705-021-05196.
    PubMed     Abstract available


    August 2021
  14. RAO JR, Rafique S, Ali A, Rehman G, et al
    Next-generation sequencing studies on the E1-HVR1 region of hepatitis C virus (HCV) from non-high-risk HCV patients living in Punjab and Khyber Pakhtunkhwa, Pakistan.
    Arch Virol. 2021 Aug 27. pii: 10.1007/s00705-021-05203.
    PubMed     Abstract available


    July 2021
  15. NASIMZADEH S, Azaran A, Jalilian S, Makvandi M, et al
    Prevalence of occult hepatitis C virus infection in beta-thalassemia major patients in Ahvaz, Iran.
    Arch Virol. 2021 Jul 18. pii: 10.1007/s00705-021-05126.
    PubMed     Abstract available


  16. MIRI HH, Fazeli P, Ali-Hassanzadeh M, Bemani P, et al
    Correlation between IL-28 polymorphism and spontaneous clearance in HCV patients: systematic review and meta-analysis.
    Arch Virol. 2021 Jul 3. pii: 10.1007/s00705-021-05141.
    PubMed     Abstract available


    June 2021
  17. PORTILHO MM, Bezerra CS, Mendonca ACDF, Marques VA, et al
    Applicability of oral fluid samples for tracking hepatitis B virus mutations, genotyping, and phylogenetic analysis.
    Arch Virol. 2021 Jun 19. pii: 10.1007/s00705-021-05122.
    PubMed     Abstract available


    May 2021
  18. LI Y, Miao Z, Li P, Zhang R, et al
    Ivermectin effectively inhibits hepatitis E virus replication, requiring the host nuclear transport protein importin alpha1.
    Arch Virol. 2021 May 14. pii: 10.1007/s00705-021-05096.
    PubMed     Abstract available


  19. DE PINA-ARAUJO IIM, Horta MA, do Amaral Mello FC, Soares CC, et al
    Human pegivirus 1 in Cabo Verde: prevalence and genotypic distribution among HIV-infected individuals.
    Arch Virol. 2021;166:1345-1353.
    PubMed     Abstract available


    April 2021
  20. LI MH, Lu Y, Sun FF, Chen QQ, et al
    Transforming growth factor beta as a possible independent factor in chronic hepatitis B.
    Arch Virol. 2021 Apr 19. pii: 10.1007/s00705-021-05062.
    PubMed     Abstract available


  21. ALI NA, Hamdy NM, Gibriel AA, El Mesallamy HO, et al
    Investigation of the relationship between CTLA4 and the tumor suppressor RASSF1A and the possible mediating role of STAT4 in a cohort of Egyptian patients infected with hepatitis C virus with and without hepatocellular carcinoma.
    Arch Virol. 2021 Apr 1. pii: 10.1007/s00705-021-04981.
    PubMed     Abstract available


    February 2021
  22. BOGLIONE L, De Benedetto I, Lupia T, Cusato J, et al
    Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study.
    Arch Virol. 2021 Feb 12. pii: 10.1007/s00705-021-04992.
    PubMed     Abstract available


  23. ABD ALLA MDA, Dawood RM, Rashed HAE, Farrag G, et al
    Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes.
    Arch Virol. 2021 Feb 3. pii: 10.1007/s00705-021-04969.
    PubMed     Abstract available


  24. RAUFF B, Amar A, Chudhary SA, Mahmood S, et al
    Interferon-lambda rs12979860 genotype association with liver fibrosis in chronic hepatitis C (CHC) patients in the Pakistani population.
    Arch Virol. 2021 Feb 2. pii: 10.1007/s00705-020-04901.
    PubMed     Abstract available


    January 2021
  25. MO L, Zeng Z, Deng R, Li Z, et al
    Hepatitis A virus-induced hsa-miR-146a-5p attenuates IFN-beta signaling by targeting adaptor protein TRAF6.
    Arch Virol. 2021 Jan 18. pii: 10.1007/s00705-021-04952.
    PubMed     Abstract available


  26. CHOUIKHA A, Khedhiri M, Triki H, Hammemi W, et al
    Focus on hepatitis C virus genotype distribution in Tunisia prior to elimination: a 16-year retrospective study.
    Arch Virol. 2021 Jan 4. pii: 10.1007/s00705-020-04918.
    PubMed     Abstract available


    September 2020
  27. FOUAD HM, Ahmed A, Reyad EM, ElSadek SM, et al
    Correction to: Hepatitis D virus seroprevalence in Egyptian HBsAgpositive children: a singlecenter study.
    Arch Virol. 2020 Sep 11. pii: 10.1007/s00705-020-04804.
    PubMed     Abstract available


  28. CAZARES-CORTAZAR A, Uribe-Noguez LA, Mata-Marin JA, Gaytan-Martinez J, et al
    A decrease in hepatitis C virus RNA to undetectable levels in chronic hepatitis C patients after PegIFNalpha + RVB or sofosbuvir + NS5A inhibitor treatment is associated with decreased insulin resistance and persistent oxidative stress.
    Arch Virol. 2020 Sep 3. pii: 10.1007/s00705-020-04797.
    PubMed     Abstract available


    August 2020
  29. FOUAD HM, Ahmed A, Reyad EM, ElSadek SM, et al
    Hepatitis D virus seroprevalence in Egyptian HBsAg-positive children: a single-center study.
    Arch Virol. 2020 Aug 3. pii: 10.1007/s00705-020-04757.
    PubMed     Abstract available


    July 2020
  30. SAFARNEZHAD TAMESHKEL F, Karbalaie Niya MH, Zamani F, Motamed N, et al
    Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) at baseline of treatment in thalassemia patients: a referral center study.
    Arch Virol. 2020 Jul 8. pii: 10.1007/s00705-020-04728.
    PubMed     Abstract available


  31. RASHTI R, Alavian SM, Moradi Y, Sharafi H, et al
    Global prevalence of HCV and/or HBV coinfections among people who inject drugs and female sex workers who live with HIV/AIDS: a systematic review and meta-analysis.
    Arch Virol. 2020 Jul 2. pii: 10.1007/s00705-020-04716.
    PubMed     Abstract available


    June 2020
  32. NIE B, Guo Y, Zhang K, Liu J, et al
    Analysis of drug-resistance-associated mutations and genetic barriers in hepatitis C virus NS5B sequences in China.
    Arch Virol. 2020 Jun 29. pii: 10.1007/s00705-020-04713.
    PubMed     Abstract available


  33. MAK D, Kramvis A
    Molecular characterization of hepatitis B virus isolated from Black South African cancer patients, with and without hepatocellular carcinoma.
    Arch Virol. 2020 Jun 5. pii: 10.1007/s00705-020-04686.
    PubMed     Abstract available


    May 2020
  34. LI Y, Shen C, Yang L, Yang Y, et al
    Correction to: Intra-host diversity of hepatitis B virus during mother-to-child transmission: the X gene may play a key role in virus survival in children after transmission.
    Arch Virol. 2020 May 6. pii: 10.1007/s00705-020-04636.
    PubMed     Abstract available


    April 2020
  35. SAID EM, Abdulaziz BA, El Kassas M, El Attar IH, et al
    High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life
    Arch Virol. 2020 Apr 30. pii: 10.1007/s00705-020-04639.
    PubMed     Abstract available


  36. LI Y, Shen C, Yang L, Yang Y, et al
    Intra-host diversity of hepatitis B virus during mother-to-child transmission: the X gene may play a key role in virus survival in children after transmission.
    Arch Virol. 2020 Apr 2. pii: 10.1007/s00705-020-04597.
    PubMed     Abstract available


    March 2020
  37. FITE RO, Kooti W, Azeze GA, Tesfaye B, et al
    Seroprevalence and factors associated with hepatitis B virus infection in blood donors in Ethiopia: a systematic review and meta-analysis.
    Arch Virol. 2020 Mar 26. pii: 10.1007/s00705-020-04591.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: